Vyne Therapeutics Inc (VYNE) has disclosed a new risk, in the Natural and Human Disruptions category.
Vyne Therapeutics Inc. faces long-term business risks stemming from climate change, including both transitional and physical threats. Transitional risks, such as shifts in energy prices, customer preferences, and new regulations, could lead to increased operational and compliance costs. Physical risks like extreme weather events may disrupt Vyne’s trials and supply chains, potentially escalating costs and impacting deliverables. Additionally, the growing focus on ESG issues increases pressure on the company to adhere to environmental and social standards, which could affect its competitiveness and brand reputation if not managed effectively.
Overall, Wall Street has a Moderate Buy consensus rating on VYNE stock based on 2 Buys.
To learn more about Vyne Therapeutics Inc’s risk factors, click here.
